FDA approves Roivant's new dermatomyositis therapy

The FDA has granted approval to a therapy developed by Roivant for the treatment of dermatomyositis, a rare autoimmune condition that causes muscle inflammation and skin rash.

The decision adds a new option to the limited arsenal for patients, offering a mechanism aimed at reducing disease activity.

The column also mentions other industry news, such as an AstraZeneca trial setback and a reported conflict of interest, but the approval is the key regulatory highlight.